Drug Trial Radar · NCT00068042
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Last checked: Nov 20, 2026Latest source record: Apr 7, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Apr 2003
Primary completion
Not stated
Study completion May 2006
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 8, 2003
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
Conditions
- Acromegaly
Interventions
PegvisomantDrug
Sandostatin LARDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with normal IGF-1 concentration at Final Visit (Week 52)
Locations
55 sites in 13 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Ann Arbor, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Chapel Hill, North Carolina
Pfizer Investigational Site
Cleveland, Ohio
Pfizer Investigational Site
Portland, Oregon
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
Charlottesville, Virginia
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia
Pfizer Investigational Site
Fitzroy, Victoria, Australia
Pfizer Investigational Site
Heidelberg, Victoria, Australia
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Le Kremlin-Bicêtre, France
Pfizer Investigational Site
Pessac, France
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Dresden, Germany
Pfizer Investigational Site
Essen, Germany
Pfizer Investigational Site
Hamburg, Germany
Pfizer Investigational Site
Heidelberg, Germany
Pfizer Investigational Site
Marburg, Germany
Pfizer Investigational Site
Piraeus, Greece
Pfizer Investigational Site
Athens, Attika/Greece, Greece
Pfizer Investigational Site
Cork, Ireland
Pfizer Investigational Site
Dublin, Ireland
Pfizer Investigational Site
Genova, Italy
Pfizer Investigational Site
Milan, Italy
Pfizer Investigational Site
Naples, Italy
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.